Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|May 13, 2011
Evaluating Library Databases for Microbial Identification: Critical Aspects and Recommendations
The ability of any system to accurately identify bacteria to the species level is based on the coverage and the accuracy of the library entries.
Advertisement
The ability of any system to accurately identify bacteria to the species level is based on the coverage and the accuracy of the library entries. The Accugenix library contains substantially more unique library entries than any other test system, containing 4,158 unique, taxonomically distinct species. Specifically, in terms of relevancy, 1,979 unique species were identified by Accugenix, analyzing 262,699 isolates from aseptic and sterile manufacturing environments collected worldwide.
A comparative analysis demonstrates that all other identification systems are just a subset of the Accugenix library, comprising less than 50% of the coverage. Furthermore, differences in coverage of bacterial species relevant to the pharmaceutical and biotechnology industries were found to be significant. Such gaps and errors in entries prohibit speciation of many relevant bacteria. The lack of coverage observed is rather forgiving, as it does not take into account assay quality and laboratory operational errors. Moreover, the ability to determine an accurate species level identification can also be influenced by poor enzymatic expressions that organisms may yield in stressed growth conditions often found in manufacturing environments when tested using phenotypic systems.
Download the complete study: Evaluating Library Databases for Microbial Identification: Critical Aspects and Recommendations
Download the library comparison: Bacterial Library Listing and Comparison April 2011
Considering outsourcing?
Contact Info:Missy Ruch
Accugenix, Inc.
223 Lake Drive
Newark, DE 19702
+1.302.294.8511
Ulrich Herber, Ph.D., Managing Director, GmbH
Accugenix, GmbH
+49 (0)621 3709 556
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement